Discover open access scientific publications

Search, annotate, share and cite publications

Publications by C Sapin

Pmu66 - Cost-Effectiveness Analysis of Ixekizumab Versus Secukinumab in Patients With Psoriatic Arthritis and Concomitant Moderate-To-Severe Psoriasis in Spain

Value in Health

English

Pmu67 - Cost-Effectiveness Analysis of Ixekizumab Versus Secukinumab in Patients With Psoriatic Arthritis and Concomitant Moderate-To-Severe Psoriasis in the United Kingdom

English

Related publications

The Effect of Psoriatic Arthritis on Ixekizumab Clinical Outcomes in Moderate-To-Severe Psoriasis Patients: A Post Hoc Analysis

Journal of the American Academy of Dermatology

Dermatology

2018

English

Cost-Effectiveness Analysis of Baricitinib Versus Adalimumab for the Treatment of Moderate-To-Severe Rheumatoid Arthritis in Spain

ClinicoEconomics and Outcomes Research

English

Ixekizumab: Targeting Plaque Psoriasis and Psoriatic Arthritis

Prescriber

Pharmacology

2019

English

Pms38 - Cost Effectiveness Analysis of Secukinumab Versus Ustekinumab for the Treatment of Psoriatic Arthritis in the United States

English

Ixekizumab Efficacy and Safety in Moderate-To-Severe Genital Psoriasis

British Journal of Dermatology

Dermatology

Medicine

2018

English

059 Ixekizumab Shows No Association With MACE in Patients With Moderate-To-Severe Psoriasis: An Integrated Safety Analysis of Clinical Trials

Journal of Investigative Dermatology

English

Matching-Adjusted Indirect Comparison: Secukinumab Versus Infliximab in Biologic-Naive Patients With Psoriatic Arthritis

Journal of Comparative Effectiveness Research

Health Policy

2019

English

540 Rapid Response in PASI, sPGA, and BSA Measures for Patients With Moderate-To-Severe Plaque Psoriasis With Ixekizumab

Journal of Investigative Dermatology

English

Amanote Research

Discover open access scientific publications

Search, annotate, share and cite publications

Publications by C Sapin

Pmu66 - Cost-Effectiveness Analysis of Ixekizumab Versus Secukinumab in Patients With Psoriatic Arthritis and Concomitant Moderate-To-Severe Psoriasis in Spain

Pmu67 - Cost-Effectiveness Analysis of Ixekizumab Versus Secukinumab in Patients With Psoriatic Arthritis and Concomitant Moderate-To-Severe Psoriasis in the United Kingdom

Related publications

The Effect of Psoriatic Arthritis on Ixekizumab Clinical Outcomes in Moderate-To-Severe Psoriasis Patients: A Post Hoc Analysis

Cost-Effectiveness Analysis of Baricitinib Versus Adalimumab for the Treatment of Moderate-To-Severe Rheumatoid Arthritis in Spain

Ixekizumab: Targeting Plaque Psoriasis and Psoriatic Arthritis

Pms38 - Cost Effectiveness Analysis of Secukinumab Versus Ustekinumab for the Treatment of Psoriatic Arthritis in the United States

Ixekizumab Efficacy and Safety in Moderate-To-Severe Genital Psoriasis

059 Ixekizumab Shows No Association With MACE in Patients With Moderate-To-Severe Psoriasis: An Integrated Safety Analysis of Clinical Trials

Matching-Adjusted Indirect Comparison: Secukinumab Versus Infliximab in Biologic-Naive Patients With Psoriatic Arthritis

540 Rapid Response in PASI, sPGA, and BSA Measures for Patients With Moderate-To-Severe Plaque Psoriasis With Ixekizumab